Cohen Matthew Gregory 4
4 · ARROWHEAD PHARMACEUTICALS, INC. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Arrowhead (ARWR) Director Matthew Cohen Receives 11,882 RSUs
What Happened
Director Matthew Cohen received a grant of 11,882 restricted stock units (RSUs) on 06/15/2026. The reported acquisition price is $0.00 (an award/grant), so no cash was paid; the filing lists the shares as an award rather than a purchase or sale.
Key Details
- Transaction date: 06/15/2026; reported on Form 4 filed 06/17/2026 (timely filing).
- Transaction type/code: A = Award/Grant. Price reported: $0.00; shares: 11,882 RSUs.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote: F1 — these RSUs were granted 06/15/2026 and will vest over three years.
- No 10b5-1 plan, tax-withholding sale, or exercise noted in this filing.
Context
RSUs are a form of equity compensation that convert into shares if and when they vest; they are typically not tradable until vesting. This transaction is an award (compensation) rather than an open-market purchase or sale, so it reflects company compensation practice rather than an immediate insider bet on the stock.
Insider Transaction Report
Form 4
Cohen Matthew Gregory
Director
Transactions
- Award
Common Stock
[F1]2026-06-15+11,882→ 11,882 total
Footnotes (1)
- [F1]Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.
Signature
/s/Matthew Gregory Cohen|2026-06-17